Recruitment Strategies Evolve for Neuronal Synuclein Disease Trials
Key Highlights
Medicine · Neurology
The Parkinson’s Progression Markers Initiative (PPMI) has evolved its recruitment strategies from focusing on untreated early-stage Parkinson’s disease to biomarker-driven enrollment of individuals with neuronal alpha-synuclein disease (NSD). The study details how PPMI expanded to include genetic cohorts and prodromal participants identified through olfactory testing and risk questionnaires targeting REM sleep behavior disorder, before moving to a biology-based enrollment model. For a neuroscientist developing preclinical models of chronic pain, this demonstration of scalable biomarker-driven cohort design is highly relevant, as it provides a methodological framework for early detection and prevention research that could be adapted to study pain conditions and their neurobiological underpinnings.
Novelty: 82%
Rigor: 90%
Significance: 88%
Validity: 91%
Clarity: 85%
Update Your Briefing Preferences
Stay curious. Stay informed —
Science Briefing
Your briefing is personalized based on your selected fields, keywords, and research interests.
